Protection Against Th17 Cells Differentiation by an Interleukin-23 Receptor Cytokine-binding Homology Region

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2012 Oct 3

PMID 23029144

Citations 9

Authors

Wei Guo

Cheng Luo

Chen Wang

Yue Zhu

Xin Wang

Xiangdong Gao

Wenbing Yao

Affiliations

Soon will be listed here.

Abstract

Th17 cells have been reported to produce proinflammatory cytokines like Interleukin-17, IL-22, and regarded as important players in various inflammatory diseases. One of the IL-12 cytokine family cytokines, IL-23, composed of p19 and p40 subunit, is known for its potential to promote Th17 development and IL-17 producing, and the IL-23/IL-17 pathway is considered to be potential therapeutic target for autoimmune inflammation responses. Knockout mice deficient in either IL-23 or IL-17 related genes can suppress the allergic responses. Several IL-23 or IL-17 neutralizing agents are being evaluated in vitro or in vivo to disrupt the IL-23/IL-17 axis. Herein, we report that prokaryotically expressed soluble IL-23 receptor cytokine-binding homology region as an endogenous extracellular receptor analogue could be a natural antagonist against IL-23/IL-17 axis. We provide evidence that IL23R-CHR can bind to IL-23 in a dose-dependent manner in vitro, and block IL-23 signal by IL23R-CHR reducing the RORγt expression, which in turn lowers the expression of IL-17/IL-22, thus protecting naive CD4+ T cells against Th17 development. Together, this study indicates the importance of IL-23 pathway in Th17 development and the negative regulation of Th17 development by IL23R-CHR, and highlights the important roles of the soluble receptor extracellular region in the therapeutic strategy of neutralizing IL-23.

Citing Articles

Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review.

Yang K, Oak A, Elewski B Am J Clin Dermatol. 2020; 22(2):173-192.

PMID: 33301128 PMC: 7727454. DOI: 10.1007/s40257-020-00578-0.

Interleukin 23 and autoimmune diseases: current and possible future therapies.

Abdo A, Tye G Inflamm Res. 2020; 69(5):463-480.

PMID: 32215665 DOI: 10.1007/s00011-020-01339-9.

Human IL-23R Cytokine-Binding Homology Region-Fc Fusion Protein Ameliorates Psoriasis via the Decrease of Systemic Th17 and ILC3 Cell Responses.

Gao Y, Bian Z, Xue W, Li Q, Zeng Y, Wang Y Int J Mol Sci. 2019; 20(17).

PMID: 31454926 PMC: 6747249. DOI: 10.3390/ijms20174170.

Structural Activation of Pro-inflammatory Human Cytokine IL-23 by Cognate IL-23 Receptor Enables Recruitment of the Shared Receptor IL-12Rβ1.

Bloch Y, Bouchareychas L, Merceron R, Skladanowska K, Van den Bossche L, Detry S Immunity. 2017; 48(1):45-58.e6.

PMID: 29287995 PMC: 5773378. DOI: 10.1016/j.immuni.2017.12.008.

Anti-inflammatory effects of interleukin-23 receptor cytokine-binding homology region rebalance T cell distribution in rodent collagen-induced arthritis.

Guo W, Yu D, Wang X, Luo C, Chen Y, Lei W Oncotarget. 2016; 7(22):31800-13.

PMID: 27177334 PMC: 5077977. DOI: 10.18632/oncotarget.9309.

References

Cornelissen F, Mus A, Asmawidjaja P, van Hamburg J, Tocker J, Lubberts E . Interleukin-23 is critical for full-blown expression of a non-autoimmune destructive arthritis and regulates interleukin-17A and RORgammat in gammadelta T cells. Arthritis Res Ther. 2009; 11(6):R194. PMC: 3003524. DOI: 10.1186/ar2893. View

Chi W, Yang P, Li B, Wu C, Jin H, Zhu X . IL-23 promotes CD4+ T cells to produce IL-17 in Vogt-Koyanagi-Harada disease. J Allergy Clin Immunol. 2007; 119(5):1218-24. DOI: 10.1016/j.jaci.2007.01.010. View

Yang X, Panopoulos A, Nurieva R, Chang S, Wang D, Watowich S . STAT3 regulates cytokine-mediated generation of inflammatory helper T cells. J Biol Chem. 2007; 282(13):9358-9363. DOI: 10.1074/jbc.C600321200. View

Cho M, Kang J, Moon Y, Nam H, Jhun J, Heo S . STAT3 and NF-kappaB signal pathway is required for IL-23-mediated IL-17 production in spontaneous arthritis animal model IL-1 receptor antagonist-deficient mice. J Immunol. 2006; 176(9):5652-61. DOI: 10.4049/jimmunol.176.9.5652. View

Oppmann B, Lesley R, Blom B, Timans J, Xu Y, Hunte B . Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 2000; 13(5):715-25. DOI: 10.1016/s1074-7613(00)00070-4. View

Dong X, Foteinou P, Calvano S, Lowry S, Androulakis I . Agent-based modeling of endotoxin-induced acute inflammatory response in human blood leukocytes. PLoS One. 2010; 5(2):e9249. PMC: 2823776. DOI: 10.1371/journal.pone.0009249. View

Aggarwal S, Ghilardi N, Xie M, de Sauvage F, Gurney A . Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem. 2002; 278(3):1910-4. DOI: 10.1074/jbc.M207577200. View

Yu R, Gallagher G . A naturally occurring, soluble antagonist of human IL-23 inhibits the development and in vitro function of human Th17 cells. J Immunol. 2010; 185(12):7302-8. DOI: 10.4049/jimmunol.1002410. View

Zhang L, Yuan S, Cheng G, Guo B . Type I IFN promotes IL-10 production from T cells to suppress Th17 cells and Th17-associated autoimmune inflammation. PLoS One. 2011; 6(12):e28432. PMC: 3232207. DOI: 10.1371/journal.pone.0028432. View

10.

Parham C, Chirica M, Timans J, Vaisberg E, Travis M, Cheung J . A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J Immunol. 2002; 168(11):5699-708. DOI: 10.4049/jimmunol.168.11.5699. View

11.

Stockinger B, Veldhoen M . Differentiation and function of Th17 T cells. Curr Opin Immunol. 2007; 19(3):281-6. DOI: 10.1016/j.coi.2007.04.005. View

12.

Veldhoen M, Hocking R, Atkins C, Locksley R, Stockinger B . TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity. 2006; 24(2):179-89. DOI: 10.1016/j.immuni.2006.01.001. View

13.

Caruso R, Fina D, Paoluzi O, Del Vecchio Blanco G, Stolfi C, Rizzo A . IL-23-mediated regulation of IL-17 production in Helicobacter pylori-infected gastric mucosa. Eur J Immunol. 2008; 38(2):470-8. DOI: 10.1002/eji.200737635. View

14.

Iwakura Y, Ishigame H . The IL-23/IL-17 axis in inflammation. J Clin Invest. 2006; 116(5):1218-22. PMC: 1451213. DOI: 10.1172/JCI28508. View

15.

LaVallie E, Rehemtulla A, Racie L, DiBlasio E, Ferenz C, Grant K . Cloning and functional expression of a cDNA encoding the catalytic subunit of bovine enterokinase. J Biol Chem. 1993; 268(31):23311-7. View

16.

Zhu J, Paul W . Heterogeneity and plasticity of T helper cells. Cell Res. 2009; 20(1):4-12. PMC: 3494736. DOI: 10.1038/cr.2009.138. View

17.

Weaver C, Harrington L, Mangan P, Gavrieli M, Murphy K . Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity. 2006; 24(6):677-688. DOI: 10.1016/j.immuni.2006.06.002. View

18.

Suen K, Turner M, Gao F, Liu B, Althage A, Slavin A . Transient expression of an IL-23R extracellular domain Fc fusion protein in CHO vs. HEK cells results in improved plasma exposure. Protein Expr Purif. 2010; 71(1):96-102. DOI: 10.1016/j.pep.2009.12.015. View

19.

Fouser L, Wright J, Dunussi-Joannopoulos K, Collins M . Th17 cytokines and their emerging roles in inflammation and autoimmunity. Immunol Rev. 2009; 226:87-102. DOI: 10.1111/j.1600-065X.2008.00712.x. View

20.

Langrish C, Chen Y, Blumenschein W, Mattson J, Basham B, Sedgwick J . IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med. 2005; 201(2):233-40. PMC: 2212798. DOI: 10.1084/jem.20041257. View